Suppr超能文献

1型人类免疫缺陷病毒O组对蛋白酶抑制剂表型耐药性的快速评估

Rapid assessment of phenotypic resistance to protease inhibitors in human immunodeficiency virus type 1 group O.

作者信息

Rodés Berta, Poveda Eva, Soriano Vincent

机构信息

Department of Infectious Diseases, Hospital Carlos III, Instituto de Salud Carlos III, Madrid, Spain.

出版信息

J Clin Microbiol. 2002 Nov;40(11):4313-6. doi: 10.1128/JCM.40.11.4313-4316.2002.

DOI:10.1128/JCM.40.11.4313-4316.2002
PMID:12409418
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC139640/
Abstract

A bacteriophage lambda-based method was used to investigate the development of resistance to protease inhibitors (PI) in one subject infected with human immunodeficiency virus (HIV) type 1 group O who underwent multiple treatment regimens over a period of 4 years. A reduction in the susceptibility to indinavir of 6-fold and a reduction in the susceptibility to saquinavir of 24-fold were recognized after long exposure to these drugs with respect to baseline. The emergence of PI resistance corresponded to the selection of amino acid changes L10V, G48M, F53L, I54V, and L90M at the protease. The results were concordant with those obtained by a drug susceptibility assay with primary HIV isolates.

摘要

采用基于λ噬菌体的方法，对一名感染1型O组人类免疫缺陷病毒（HIV）的受试者进行了研究，该受试者在4年期间接受了多种治疗方案，以调查其对蛋白酶抑制剂（PI）的耐药性发展情况。与基线相比，长期接触这些药物后，发现茚地那韦敏感性降低了6倍，沙奎那韦敏感性降低了24倍。PI耐药性的出现与蛋白酶处氨基酸变化L10V、G48M、F53L、I54V和L90M的选择相对应。结果与用原发性HIV分离株进行的药物敏感性试验所得结果一致。

相似文献

1
Rapid assessment of phenotypic resistance to protease inhibitors in human immunodeficiency virus type 1 group O.
J Clin Microbiol. 2002 Nov;40(11):4313-6. doi: 10.1128/JCM.40.11.4313-4316.2002.
2
Discordant genotypic interpretation and phenotypic role of protease mutations in HIV-1 subtypes B and G.
J Antimicrob Chemother. 2009 Mar;63(3):593-9. doi: 10.1093/jac/dkn526. Epub 2009 Jan 10.
3
Genetic variation and susceptibilities to protease inhibitors among subtype B and F isolates in Brazil.
Antimicrob Agents Chemother. 1999 Feb;43(2):253-8. doi: 10.1128/AAC.43.2.253.
4
Biological characterization of human immunodeficiency virus type 1 subtype C protease carrying indinavir drug-resistance mutations.
J Gen Virol. 2006 May;87(Pt 5):1303-1309. doi: 10.1099/vir.0.81517-0.
5
Fluorometric assay for phenotypic differentiation of drug-resistant HIV mutants.
Sci Rep. 2015 May 19;5:10323. doi: 10.1038/srep10323.
6
Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir.
J Virol. 2001 Jan;75(2):589-94. doi: 10.1128/JVI.75.2.589-594.2001.
7
Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations.
AIDS. 1999 Feb 25;13(3):359-65. doi: 10.1097/00002030-199902250-00008.
8
Antagonism between human immunodeficiency virus type 1 protease inhibitors indinavir and saquinavir in vitro.
J Infect Dis. 1997 Jul;176(1):265-8. doi: 10.1086/517263.
9
Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes.
J Clin Virol. 2004 Nov;31(3):215-20. doi: 10.1016/j.jcv.2004.03.015.
10
Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors.
Antimicrob Agents Chemother. 2007 Feb;51(2):604-10. doi: 10.1128/AAC.00870-06. Epub 2006 Nov 20.

引用本文的文献

1
HIV-1 Group O Genotypes and Phenotypes: Relationship to Fitness and Susceptibility to Antiretroviral Drugs.
AIDS Res Hum Retroviruses. 2016 Jul;32(7):676-88. doi: 10.1089/AID.2015.0318. Epub 2016 Mar 16.

本文引用的文献

1
The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors.
AIDS Rev. 2000;2(4):211-228.
2
Naturally occurring sequence polymorphisms within HIV type 1 group O protease.
AIDS Res Hum Retroviruses. 2001 Nov 1;17(16):1555-61. doi: 10.1089/08892220152644269.
3
Rapid genetic selection of inhibitor-resistant protease mutants: clinically relevant and novel mutants of the HIV protease.
AIDS Res Hum Retroviruses. 2001 Sep 1;17(13):1249-55. doi: 10.1089/088922201750461302.
4
Monitoring the response to antiretroviral therapy in HIV-1 group O infected patients using two new RT-PCR assays.
J Med Virol. 2001 Jul;64(3):217-22. doi: 10.1002/jmv.1039.
5
Natural residues versus antiretroviral drug-selected mutations in HIV type 1 group O reverse transcriptase and protease related to virological drug failure in vivo.
AIDS Res Hum Retroviruses. 2000 Sep 20;16(14):1385-94. doi: 10.1089/08892220050140937.
6
A bacteriophage lambda-based genetic screen for characterization of the activity and phenotype of the human immunodeficiency virus type 1 protease.
Antimicrob Agents Chemother. 2000 May;44(5):1132-9. doi: 10.1128/AAC.44.5.1132-1139.2000.
7
Analysis of pol gene heterogeneity, viral quasispecies, and drug resistance in individuals infected with group O strains of human immunodeficiency virus type 1.
J Virol. 1998 Nov;72(11):9002-15. doi: 10.1128/JVI.72.11.9002-9015.1998.
8
A genetic screen for the isolation and characterization of site-specific proteases.
Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):2828-33. doi: 10.1073/pnas.95.6.2828.
9
Group O human immunodeficiency virus-1 infections.
Infect Dis Clin North Am. 1998 Mar;12(1):39-46. doi: 10.1016/s0891-5520(05)70407-4.
10
Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses.
J Virol. 1997 Nov;71(11):8893-8. doi: 10.1128/JVI.71.11.8893-8898.1997.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验